Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 7:13 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 205 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: levonorgestrel Clear all

Conditions: Emergency Contraception
Interventions: CDB-2914, levonorgestrel; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older · Female only
Enrollment: 1,672 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1999 – 2001
U.S. locations: 6
States / cities: Los Angeles, California • Denver, Colorado • New York, New York + 3 more

Conditions: Contraception
Interventions: Diazepam, Lidocaine, Placebo pill, Placebo injection; Drug · Other
Lead sponsor: TriHealth Inc.; Other
Eligibility: 18 Years and older · Female only
Enrollment: 61 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Breakthrough Bleeding
Interventions: DR-1031, Seasonale®, Portia®; Drug
Lead sponsor: Duramed Research; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 567 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 50
States / cities: Huntsville, Alabama • Tucson, Arizona • Little Rock, Arkansas + 45 more

Conditions: HIV Infections, Tuberculosis
Interventions: Levonorgestrel (LNG); Drug
Lead sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections; Network
Eligibility: 16 Years and older · Female only
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 7
States / cities: Chicago, Illinois • New York, New York • Chapel Hill, North Carolina + 3 more

Conditions: Ovarian Carcinoma
Interventions: Laboratory Biomarker Analysis, Levonorgestrel, Placebo; Other · Drug
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: 30 Years and older · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 66
States / cities: Duarte, California • Los Angeles, California • Orange, California + 46 more

Conditions: Contraception
Interventions: Ulipristal Acetate, Levonorgestrel (LNG)/Ethinyl estradiol birth control pill; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Unplanned Pregnancy
Interventions: Levonorgestrel-Releasing Intrauterine Contraceptive System (LNG-IUS), 52 Mg, 5 Year Duration; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 21 Years to 45 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Contraceptives, Oral
Interventions: Lybrel, Doxycycline, Oracea, Placebo, Doxycycline 100bid x5 days at the time of bleeding, Subantimicrobial doxycycline daily, placebo daily; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 131 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2011
U.S. locations: 2
States / cities: Honolulu, Hawaii • Portland, Oregon

Conditions: HIV, Contraception
Interventions: Depot medroxyprogesterone acetate (DMPA), Etonogestrel implant (Eng-Implant), Levonorgestrel intrauterine device (Lng-IUD), ParaGard® T 380A Intrauterine Copper Contraceptive; Drug · Device
Lead sponsor: Lisa Haddad; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 59 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2019
U.S. locations: 4
States / cities: Atlanta, Georgia

Conditions: Menorrhagia
Interventions: Levonorgestrel 52 mg intrauterine system; Combination Product
Lead sponsor: Medicines360; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 105 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 29
States / cities: Scottsdale, Arizona • Sacramento, California • San Diego, California + 25 more

Conditions: Contraception
Interventions: Lidocaine, Lubricant; Drug
Lead sponsor: University of Tennessee; Other
Eligibility: Female only
Enrollment: 210 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Chattanooga, Tennessee

Conditions: Contraception, Mood Change
Interventions: Mirena, Paraguard; Device
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 39 Years · Female only
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Contraception
Interventions: Etonogestrel Implant; Device
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 1,076 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2021
U.S. locations: 2
States / cities: Indianapolis, Indiana • St Louis, Missouri

Conditions: Contraception, Women at Risk for Pregnancy
Interventions: LevoCept; Drug
Lead sponsor: Sebela Women's Health Inc.; Industry
Eligibility: Up to 45 Years · Female only
Enrollment: 1,525 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2032
U.S. locations: 27
States / cities: Berkeley, California • Los Angeles, California • Sacramento, California + 20 more

Conditions: Contraception
Interventions: Kyleena; Drug
Lead sponsor: Bayer; Industry
Eligibility: Female only
Enrollment: 1,134 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 12
States / cities: Lakewood, Colorado • Sarasota, Florida • Wellington, Florida + 9 more

Conditions: Contraception
Interventions: IUD insertion, Povidone-Iodine, Chlorhexidine, Oxygen, Nitrous oxide; Procedure · Drug · Other
Lead sponsor: University of New Mexico; Other
Eligibility: 12 Years and older · Female only
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Contraception
Interventions: IUD; Device
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older · Female only
Enrollment: 404 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 4
States / cities: La Jolla, California • San Diego, California • Chicago, Illinois + 1 more

Conditions: Levonorgestrel, Intrauterine Systems, Prevention, Endometrial Cancer
Interventions: Survey using a questionnaire; Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Obesity, Contraception
Interventions: UPA-ECx1, UPA-ECx2; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Migraine
Interventions: 91-day Levonorgestrel Oral Contraceptive, Placebo; Drug
Lead sponsor: Duramed Research; Industry
Eligibility: 18 Years to 34 Years · Female only
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 22
States / cities: La Mesa, California • San Diego, California • San Francisco, California + 18 more

Conditions: Endometrial Cancer
Interventions: medroxyprogesterone, ethinyl estradiol, norgestrel, laboratory biomarker analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 25 Years to 50 Years · Female only
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Healthy
Interventions: LY4515100 via SAD, LY4515100 via MAD, LY4515100, Itraconazole, Caffeine, Digoxin, Iohexol, Metformin, Rosuvastatin, Placebo, Midazolam, Levonorgestrel, Ethinyl Estradiol; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 209 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Dallas, Texas • Madison, Wisconsin

Conditions: Ovulation Suppression
Interventions: levonorgestrel and ethinyl estradiol; Drug
Lead sponsor: Agile Therapeutics; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 123 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 11
States / cities: Tucson, Arizona • San Diego, California • Denver, Colorado + 8 more

Conditions: Healthy Participants
Interventions: AZD5004, Itraconazole, EE/LNG; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Baltimore, Maryland

Search by objective public record fields.

Efficacy Trial of CDB 2914 for Emergency Contraception

Effect of Multimodal Analgesia on Pain With Insertion of Levonorgestrel-releasing IUD

A Study to Evaluate Bleeding Patterns With Three Different Doses of DR-1031 Compared to Seasonale

Pharmacokinetic Study to Evaluate Double-Dose Levonorgestrel Emergency Contraception in Combination With Efavirenz-Based Antiretroviral Therapy or Rifampicin-Containing Anti-Tuberculosis Therapy

Levonorgestrel in Preventing Ovarian Cancer in Patients at High Risk for Ovarian Cancer

Impact of Combined Hormonal Contraceptives on UPA

A Pilot Study of Early Postpartum Intrauterine Contraception

A Study of Continuous Oral Contraceptives and Doxycycline

Impact of Hormonal Contraception on HIV Acquisition and Transmission Risk

Study of a Levonorgestrel 52 mg Intrauterine System for the Treatment of Heavy Menstrual Bleeding

Topical Lidocaine on the Cervix and Intra-Cervical Prior to Insertion of Intrauterine Devices

Stress Hormones and IUDs

Effectiveness of Prolonged Use of IUD/Implant for Contraception

Evaluation of the Efficacy, Safety, and Tolerability of LevoCept

KYleena Satisfaction Study / Observational Study on User Satisfaction With the Levonorgestrel Intrauterine Delivery System Kyleena (LNG-IUS 12) in New Contraceptive Users and After Switching From Another Contraceptive Method

Nitrous Oxide for Pain Management of Intrauterine Device (IUD) Insertion

Early vs. Interval Postpartum IUD Insertion

Development of a Shared Decision Tool to Facilitate Uptake of the Levonorgestrel-releasing Intrauterine System for the Primary Prevention of Endometrial Cancer

Effectiveness of Orally Dosed Emergency Contraception in Obese Women - UPA

A Multicenter Study to Evaluate the Efficacy of a 91-Day Extended Cycle Oral Contraceptive for Menstrually-Related Migraine Headaches

Hormone Therapy in Preventing Endometrial Cancer in Patients With a Genetic Risk For Hereditary Nonpolyposis Colon Cancer

A Study of LY4515100 in Healthy Participants

Evaluation of Pharmacodynamic Effects on Ovulation and Cycle Control

A Study to Investigate the Impact of Multiple Doses of Itraconazole on AZD5004 in Healthy Participants and Multiple Doses of AZD5004 on Combined Oral Ethinyl Oestradiol and Levonorgestrel in Healthy Female Participants